About

Kate T. Anderson is an Associate Professor at the Mary Lou Fulton College for Teaching and Learning Innovation at Arizona State University, with additional affiliations including the Institute for Social Science Research. Her research draws on sociolinguistics, anthropology, and literacy studies, with primary methodological expertise in discourse analysis, ethnography, and other forms of qualitative inquiry focused on classroom interactions and ideologies of language and learning. Her work interrogates the role of ideologies in constructing social differences related to ability, race, language learning, and other social categories, aiming to understand how talk, action, and policy shape students' opportunities to learn and be viewed as successful. Professor Anderson is interested in addressing educational inequities through interdisciplinary research and practice. She is the lead editor of the journal Linguistics and Education and chairs the Language and Social Processes special interest group in the American Education Research Association. She teaches qualitative methods and linguistics courses in bilingual education within the division of educational leadership and innovation. Her current projects include examining how teachers interpret the abilities and needs of linguistically diverse students, especially refugees and immigrants, with the goal of helping local teachers serve these populations better. Her research also explores intersections between stakeholder assumptions, community needs, and educational realities, with plans to expand this work across the U.S. through online master's programs.

Research topics

• Medicine
• Internal medicine
• Political Science
• Computer Science
• Biology
• Computational biology
• Virology
• Genetics
• Oncology
• Pathology
• Immunology

Selected publications

• Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

  Frontiers in Bioengineering and Biotechnology · 2023 · 107 citations

  Senior authorCorresponding
  • Medicine
  • Computational biology
  • Biology

  CRISPR clinical trials make progress, the challenge of immunogenicity remains a significant roadblock to the clinical availability and utility of CRISPR therapeutics. In this review, we examine what is currently known about the immunogenicity of CRISPR therapeutics and discuss several considerations to mitigate immunogenicity for the design of safe and clinically translatable CRISPR therapeutics.

  DOI

• Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study

  BMJ · 2021 · 77 citations

  • Computer Science
  • Computer Science
  • Medicine

  OBJECTIVE: To estimate population health outcomes with delayed second dose versus standard schedule of SARS-CoV-2 mRNA vaccination. DESIGN: Simulation agent based modeling study. SETTING: Simulated population based on real world US county. PARTICIPANTS: The simulation included 100 000 agents, with a representative distribution of demographics and occupations. Networks of contacts were established to simulate potentially infectious interactions though occupation, household, and random interactions. INTERVENTIONS: Simulation of standard covid-19 vaccination versus delayed second dose vaccination prioritizing the first dose. The simulation runs were replicated 10 times. Sensitivity analyses included first dose vaccine efficacy of 50%, 60%, 70%, 80%, and 90% after day 12 post-vaccination; vaccination rate of 0.1%, 0.3%, and 1% of population per day; assuming the vaccine prevents only symptoms but not asymptomatic spread (that is, non-sterilizing vaccine); and an alternative vaccination strategy that implements delayed second dose for people under 65 years of age, but not until all those above this age have been vaccinated. MAIN OUTCOME MEASURES: Cumulative covid-19 mortality, cumulative SARS-CoV-2 infections, and cumulative hospital admissions due to covid-19 over 180 days. RESULTS: 236 for 90%, 80%, and 70% first dose efficacy, respectively. The delayed second dose strategy was optimal for vaccine efficacies at or above 80% and vaccination rates at or below 0.3% of the population per day, under both sterilizing and non-sterilizing vaccine assumptions, resulting in absolute cumulative mortality reductions between 26 and 47 per 100 000. The delayed second dose strategy for people under 65 performed consistently well under all vaccination rates tested. CONCLUSIONS: A delayed second dose vaccination strategy, at least for people aged under 65, could result in reduced cumulative mortality under certain conditions.

  DOI

• Acknowledgments

  Cornell University Press eBooks · 2020

  • Political Science
  • Political Science

  The welcome occasion at last arises to thank the many people who contributed to this project both directiy and indirectly, many of them over a long period of years and in multiple ways.First thanks go to

  DOI

• Biomarkers and Strategies for Early Detection of Ovarian Cancer

  Cancer Epidemiology Biomarkers & Prevention · 2020 · 112 citations

  • Medicine
  • Oncology
  • Computational biology

  Early detection of ovarian cancer remains an important unmet medical need. Effective screening could reduce mortality by 10%-30%. Used individually, neither serum CA125 nor transvaginal sonography (TVS) is sufficiently sensitive or specific. Two-stage strategies have proven more effective, where a significant rise above a woman's baseline CA125 prompts TVS and an abnormal sonogram prompts surgery. Two major screening trials have documented that this strategy has adequate specificity, but sensitivity for early-stage (I-II) disease must improve to have a greater impact on mortality. To improve the first stage, different panels of protein biomarkers have detected cases missed by CA125. Autoantibodies against TP53 have detected 20% of early-stage ovarian cancers 8 months before elevation of CA125 and 22 months before clinical diagnosis. Panels of autoantibodies and antigen-autoantibody complexes are being evaluated with the goal of detecting >90% of early-stage ovarian cancers, alone or in combination with CA125, while maintaining 98% specificity in control subjects. Other biomarkers, including micro-RNAs, ctDNA, methylated DNA, and combinations of ctDNA alterations, are being tested to provide an optimal first-stage test. New technologies are also being developed with greater sensitivity than TVS to image small volumes of tumor.

  DOI

Recent grants

• NIH Grant UG3CA211415

  NIH · $715k · 2019

• NIH Grant K08CA088444

  NIH · $634k · 2005

• Novel approaches to study immune responses to post translational modifications for cancer detection

  NIH · $2.6M · 2016–2022

• NIH Grant P01CA078378

  NIH · $20.0M · 2016

• NIH Grant U01CA117374

  NIH · $6.2M · 2016

Frequent coauthors

• Joshua LaBaer

  Arizona State University

  86 shared

• Joachim L. Schultze

  University of Bonn

  72 shared

• Robert H. Vonderheide

  72 shared

• Lee M. Nadler

  69 shared

• Britta Maecker

  65 shared

• Michael S. von Bergwelt‐Baildon

  63 shared

• Ibrahim G Tsolakian

  University of Toledo

  60 shared

• Lori Koslosky

  Fox Chase Cancer Center

  53 shared

Labs

• Kate Anderson LabPI

Education

• Ph.D., Sociolinguistics

  University of Georgia

  2006

• Other, Qualitative Studies

  The University of Georgia

  2006

• B.A., Music

  New York University

  2000

Similar researchers at Arizona State University

• Greg Asnerh-157
• Philip Christensenh-130
• Jianguo Wuh-119
• Carolyn Comptonh-118
• Osvaldo Salah-114